TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Information Visualizations to Facilitate HIV-related Patient-provider Communication (Info Viz: HIV)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (≥) 18 years of age~* Spanish-speaking~* Living with HIV and have a detectable viral load~* Attend Clínica de Familia La Romana~* Plan to receive care at the same clinic for the next year~Exclusion Criteria:~* Does not meet inclusion criteria~* Not able to understand study procedures or provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): Participants in the intervention group will receive health education using infographics (Infographic Intervention) during their regularly scheduled clinic visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Of Bacterial Lysate In Asthmatic Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children of both genders aged 6 to 16 years.~2. Allergic asthma diagnosis with at least one perennial allergen according to the Global Strategy for Asthma Management and Prevention (GINA 2012 guidelines) prior to screening visit.~3. Patient shows clinical characteristics of partly controlled or uncontrolled asthma according to GINA 2012.~4. Already treated with SABA prn and ICS or ICS + LABA during the previous 3 months.~5. Patient shows antigen-specific IgE against HDM ≥ class 2 or positive skin prick test or RAST for at least one perennial allergen.~6. Patient who had at least 2 exacerbations of asthma within the 12-mo period before V1.~7. Patient not treated with Polyvalent Mechanical Bacterial Lysate (Ismigen®) within the previous 6 months prior to Visit 1.~Exclusion Criteria:~1. Patient received mechanical or any other bacterial lysate immunostimulation within the previous 6 months before Visit 1.~2. Patient received oral/subcutaneous allergen-immunotherapy within the previous 6 months before Visit 1.~3. History of near fatal asthma (e.g. brittle asthma, hospitalization for asthma exacerbation in Intensive Care Unit).~4. Pregnant or breastfeeding woman.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- ISMIGEN (Type: EXPERIMENTAL): Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
- PLACEBO (Type: PLACEBO_COMPARATOR): Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 18 years of age~* Clinical diagnosis of DVT or PE~Exclusion Criteria:~* Contraindications for enoxaparin or warfarin~* Active bleeding or high risk for serious bleeding~* Short life expectancy~* Uncontrolled high blood pressure~* Significantly impaired kidney or liver function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban (Type: ACTIVE_COMPARATOR): apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
- Enoxaparin + Warfarin (Type: EXPERIMENTAL): Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with clinically defined multiple sclerosis~* All patients must be able to complete two trials of a timed 25 foot walk~Exclusion Criteria:~* Female patients who are either pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo control
- Fampridine-SR (Type: ACTIVE_COMPARATOR): 10 mg b.i.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with CD19+ Refractory or Relapsed B-ALL（At least 2 prior combination chemotherapy regimens）~2. To be aged 3 to 75 years~3. Blast in blood ≤ 30%~4. ECOG score ≤2~5. Women of childbearing potential must have a urine pregnancy test taken and proven negative prior to the treatment. All patients agree to use reliable methods of contraception during the trial period and until follow-up for the last time.~6. Voluntary participation in the clinical trials and sign the informed consent.~Exclusion Criteria:~1. Intracranial hypertension or unconsciousness~2. Respiratory failure~3. CD19 negative~4. Disseminated intravascular coagulation~5. ALT /AST\>3 x normal value; Creatinine\> 1.5 x normal value; Bilirubin \>2.0 x normal value~6. Hematosepsis or Uncontrolled active infection~7. Uncontrolled diabetes~8. Abalienation;~9. WHO Sscore \>3~10. Patients in pregnancy or breast-feeding period~11. Previously treatment with any gene therapy products~12. Any uncontrolled medical disorders that the researchers consider are not eligible to participate the clinical trial~13. Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IM19 CART (Type: EXPERIMENTAL): All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-resectable, histologically confirmed, epithelial growth factor receptor(EGFR)-positive or negative colorectal cancer~* WHO Performance status 0 or 1~* Signed written informed consent~* ≥ 18 years of age~* Effective contraception for both male and female subjects if the risk of conception exists~* Adequate bone marrow function: neutrophil blood cell count (NBC) ≥ 1.5 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, hemoglobin ≥ 5.96 mmol/L (10 g/dL)~* Adequate liver and renal function: bilirubin ≤ 1.5 x upper normal level (UNL) and not increasing more than 25% within the last 4 weeks; ASAT and ALAT ≤ 5 x UNL; serum creatinine ≤ 1.5 x UNL.~Exclusion Criteria:~* Previous exposure to epidermal growth factor receptor-targeting therapy~* Previous chemotherapy for colorectal cancer except for adjuvant treatment with progression of disease documented \> 6 months after end of adjuvant treatment or 5-FU in combination with radiotherapy for rectal cancer~* Radiotherapy or major abdominal or thoracic surgery within the last 4 weeks before inclusion.~* Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy.~* Investigational agents or participation in clinical trials within 30 days before start of the treatment in study.~* Clinically relevant coronary disease or myocardial infarction within 12 months before study entry.~* Peripheral neuropathy \> CTC (Common Toxicity Criteria)grade I~* Inflammatory bowel disease~* Previous malignancy (except for colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)~* History of severe psychiatric illness~* Drug or alcohol abuse~* Known hypersensitivity reaction to any of the components of study treatment~* Pregnancy (absence to be confirmed by b-hCG (pregnancy-) test) or lactation period~* Brain metastasis and/or leptomeningeal disease (known or suspected)~* Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab+ FOLFOXIRI (Type: EXPERIMENTAL): Cetuximab and Irinotecan, Oxaliplatin, 5FU and Folinic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premature infant admitted to the Neonatal Intensive Care Unit at Women \& Infants Hospital~* Receiving full enteral feeds of either preterm or transitional formula or fortified breast milk~* Anticipated to have a minimum stay of two weeks~Exclusion Criteria:~* Prior exposure to antifungal drugs

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): This group receives no feeding supplement.
- MCT Oil (Type: EXPERIMENTAL): This group is supplemented with MCT oil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with a corrected decimal visual acuity (VA) of 0.5 or better in both eyes.~Exclusion Criteria:~* Subjects with known hypersensitivity or contraindications to latanoprostene bunod, or any of the ingredients in the study drug.~* Subjects with known contraindications to NO treatment.~* Subjects who are unable to discontinue contact lens use at least 7 days prior to Visit 2 (Day 0/1/2) and during the 14 to 15-day study treatment period.~* Subjects who are unable to discontinue the use of all topical ophthalmic medications, including artificial tears, at least 7 days prior to Visit 2 (Day 0/1/2) and during the 14 to 15-day study treatment period.~* Subjects with any condition that prevents reliable applanation tonometry in either eye.~* Subjects with glaucoma in either eye.~* Subjects with any condition that prevents clear visualization of the fundus.~* Subjects who are monocular.~* Subjects with aphakia in either eye.~* Subjects with an active corneal disease in either eye.~* Subjects with severe dry eye in either eye.~* Subjects with a history/diagnosis of a clinically significant or progressive retinal disease in either eye.~* Subjects with any intraocular infection or inflammation within 3 months (90 days) prior to Visit 1 (Screening).~* Subjects with a history of ocular laser surgery within the 3 months (90 days) prior to Visit 1 (Screening).~* Subjects with a history of incisional ocular surgery or severe trauma.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Latanoprostene Bunod (Type: EXPERIMENTAL): Participants will instill 1 drop of latanoprostene bunod 0.024% topically into each eye QD in the evening for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Intravenous Fluids in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All children (3 months to 12 years) who are admitted to pediatric ward or pediatric ICU, who require exclusive intravenous maintenance fluid therapy for at least 24 hours will be eligible for the study~Exclusion Criteria:~* Children with illness that have primary fluid and electrolyte imbalance such as:~  * Shock: Defined as acute circulatory failure resulting in decreased tissue perfusion and manifesting as altered sensorium, hypothermia (\<35oC), tachycardia, prolonged capillary filling time (\>3 seconds), hypotension (BP \< 5th percentile for age), oliguria (\<0.5 ml/kg/hr), hypoxemia, hyperlactatemia, requirement of fluid bolus and/ or vasopressors.~ * Diarrhea and Dehydration: Children presenting with diarrhea and features of dehydration: lethargy, irritability and altered sensorium, thirst, decreased urine output, sunken eyes \& dry mucous membranes, loss of skin elasticity.; children with ongoing diarrhea will be excluded even if there is no dehydration.~ * Fluid Overload: Cirrhosis, Congestive heart failure, Acute and Chronic renal failure, Nephrotic syndrome.~* Abnormal serum sodium or Hyperglycemia at Presentation:~  * Hyponatremia : serum sodium \< 130 mmol/L.~ * Hypernatremia : serum sodium \>150 mmol/L.~ * Hyperglycemia: blood glucose \> 180 mg/ dl.~* Severe Protein Energy Malnutrition: Defined as grade III (50-59% of expected weight for age) and grade IV (less than 50% of expected weight for age) as per IAP classification.~* Child who is receiving drugs which cause abnormality in serum sodium such as diuretics, vasopressin, etc.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Isotonic fluid group (Type: ACTIVE_COMPARATOR): Normal saline in 5% dextrose at standard maintenance rate
- Fluid restriction group (Type: ACTIVE_COMPARATOR): Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose
- Hypotonic fluid group (Type: ACTIVE_COMPARATOR): N/5 saline in 5% dextrose at standard maintenance rate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Continuous Positive Airway Pressure (CPAP) Treatment on Glucose Control in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects with type 2 diabetes on a stable medication regimen (no change in diabetic medications in the previous 3 months) will be eligible.~Exclusion Criteria:~* Subjects on insulin will be excluded.~* Subjects with unstable cardiopulmonary disease, painful neuropathy, significant psychiatric illness, cognitive impairment and pregnancy will be excluded.~* Shift workers~* Subjects having traveled across \>2 time zones less than one month prior to the study~* Diagnosis of a sleep disorder other than OSA by screening polysomnography~* Previous treatment with positive airway pressure or supplemental oxygen~* Requirement of supplemental oxygen or bi-level positive airway pressure for OSA treatment during titration~* Claustrophobia or other conditions of CPAP intolerance,~* Presence of active infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active CPAP therapy (Type: ACTIVE_COMPARATOR): 7 days of treatment in the laboratory with active CPAP therapy.
- Sham CPAP therapy (Type: SHAM_COMPARATOR): 7 days of sham CPAP therapy in the laboratory.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Two Regimens for Medical Abortion: Mifepristone+Misoprostol Versus Misoprostol Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age \< 63 days by LMP, ultrasound or clinical assessment.~* General good health including absence of conditions which contraindicate the use of mifepristone and misoprostol for pregnancy termination.~* Agrees to return for follow-up visit and willing to provide an address and/or telephone number for purposes of follow-up.~* Able to consent to study participation.~Exclusion Criteria:~* Gestational age \> 63 days~* Confirmed or suspected ectopic or molar pregnancy~* Contraindications to medical abortion including IUD in place (must be removed before procedure), chronic adrenal failure, concurrent long-term corticosteroid therapy, history of allergy to mifepristone, misoprostol or prostaglandin, hemorrhagic disorders or concurrent anticoagulant therapy, inherited porphyries.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- mifepristone+misoprostol (Type: EXPERIMENTAL): 200 mg mifepristone+ 800 mcg buccal misoprostol
- misoprostol (Type: EXPERIMENTAL): 800 mcg buccal misoprostol+placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of type 2 diabetes mellitus prior to informed consent~* Male and female patients on diet and exercise regimen for 12 weeks prior to informed consent who are:~  * drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,~ * pre-treated with one oral antidiabetic drug (except sulfonylurea and thiazolidinedione); the present antidiabetic therapy has to be unchanged for at least 12 weeks prior to the informed consent. (Sulfonylurea is permitted as pre-treatment drug only if the dose is equal or less than a half of daily maximum approval dose.)~* Glycosylated haemoglobin (HbA1c) at Visit 1 (screening)~  * for patients without antidiabetic therapy : HbA1c \>=7.0 to =\<10.0%~ * for patients with one oral antidiabetic drug : HbA1c \>=7.0 to =\<9.5%~Exclusion criteria:~* Uncontrolled hyperglycaemia with a glucose level \>240 mg/dL (\>13.3 mmol/L)~* Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal disease (MDRD) formula)~* Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent~* Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin low dose (Type: EXPERIMENTAL): Empagliflozin low dose tablet once daily
- Empagliflozin high dose (Type: EXPERIMENTAL): Empagliflozin high dose tablet once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture in the Treatment of Gulf War Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion~1. deployed to the Gulf Theater of operations, as defined by 38 CFR 3.317, includes Iraq, Kuwait, Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, Oman, the Gulf of Aden, the Gulf of Oman, the Persian Gulf, the Arabian Sea, the Red Sea, and the airspace above all of these locations between August 1990 and the present date,~2. they have at least 2 of the following symptoms from the 3 CDC clusters of symptom that have lasted for more than 6 months. Each symptom cluster must be characterized as mild-moderate or severe with at least one symptom in each cluster required to be severe. The clusters are:~A-Fatigability~* fatigue 24 hours or more after exertion B-Mood and Cognition~* feeling depressed or~* feeling irritable or~* difficulty thinking or concentrating or~* feeling worried, tense, anxious or~* problems finding words or~* problems getting to sleep C-Musculoskeletal~* joint pain or muscle pain~Exclusion:~* Currently enrolled in another clinical trial~* Have another disease that likely could account for the symptoms, as determined by our Medical Monitor~* Severe psychiatric illness (in the last 2 years psychiatric hospitalization, suicidal attempt, alcohol or substance abuse, use of antipsychotic medication) as measured by the Primary Care Evaluation of Mental Disorder (Prime MD).~* Unable to complete the protocol on based on the evaluation of the Medical Monitor

- Gender: ALL
- Minimum Age: 39 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bi-weekly acupuncture treatment (Type: EXPERIMENTAL): Bi-weekly acupuncture treatment
- Wait list (Type: ACTIVE_COMPARATOR): Wait list for 2 months followed by weekly acupuncture for 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete